BlackRock
RVMD icon

BlackRock’s Revolution Medicines RVMD Stock Holding History

BlackRock’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.56B Buy
13,695,790
+2,483,084
+22% +$363M 0.04% 375
2026
Q1 		$1.09B Buy
11,212,706
+2,286,050
+26% +$231M 0.02% 648
2025
Q4 		$711M Buy
8,926,656
+598,898
+7% +$39.3M 0.01% 866
2025
Q3 		$389M Sell
8,327,758
-333,635
-4% -$13.1M 0.01% 1251
2025
Q2 		$319M Sell
8,661,393
-6,030,999
-41% -$232M 0.01% 1331
2025
Q1 		$520M Sell
14,692,392
-27,156
-0.2% -$1.1M 0.01% 1005
2024
Q4 		$644M Buy
14,719,548
+852,690
+6% +$43M 0.01% 917
2024
Q3 		$629M Buy
13,866,858
+458,145
+3% +$19.9M 0.01% 908
2024
Q2 		$520M Buy
13,408,713
+1,100,711
+9% +$41.1M 0.01% 980
2024
Q1 		$397M Sell
12,308,002
-646,312
-5% -$19.2M 0.01% 1191
2023
Q4 		$372M Buy
12,954,314
+4,082,900
+46% +$98.1M 0.01% 1233
2023
Q3 		$246M Buy
8,871,414
+613,798
+7% +$18.2M 0.01% 1406
2023
Q2 		$221M Buy
8,257,616
+791,842
+11% +$19.4M 0.01% 1507
2023
Q1 		$162M Buy
7,465,774
+889,828
+14% +$21.9M ﹤0.01% 1702
2022
Q4 		$157M Buy
6,575,946
+222,487
+4% +$4.73M ﹤0.01% 1699
2022
Q3 		$125M Buy
6,353,459
+949,655
+18% +$20.9M ﹤0.01% 1813
2022
Q2 		$105M Buy
5,403,804
+63,516
+1% +$1.24M ﹤0.01% 1971
2022
Q1 		$136M Sell
5,340,288
-134,931
-2% -$2.94M ﹤0.01% 1932
2021
Q4 		$138M Buy
5,475,219
+369,181
+7% +$10.4M ﹤0.01% 1995
2021
Q3 		$140M Buy
5,106,038
+287,908
+6% +$8.38M ﹤0.01% 1980
2021
Q2 		$153M Buy
4,818,130
+987,056
+26% +$34.5M ﹤0.01% 1973
2021
Q1 		$176M Buy
3,831,074
+318,987
+9% +$14.3M 0.01% 1819
2020
Q4 		$139M Buy
3,512,087
+975,677
+38% +$38.6M ﹤0.01% 1865
2020
Q3 		$88.3M Buy
2,536,410
+1,430,172
+129% +$39.6M ﹤0.01% 1955
2020
Q2 		$34.9M Buy
1,106,238
+307,981
+39% +$9.68M ﹤0.01% 2461
2020
Q1 		$17.5M Buy
+798,257
New +$22.1M ﹤0.01% 2682

Other funds holding RVMD

FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

BlackRock's RVMD Position: Q2 2026 in Review

BlackRock increased its Revolution Medicines (RVMD) stake by 22% in Q2 2026, buying an estimated $363M and bringing the position to 13,695,790 shares worth $2.56B. The position accounts for 0.04% of the portfolio, ranked #375.

BlackRock first reported a position in RVMD in Q1 2020 and has held it in 26 quarters since. 690 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • BlackRock held 13,695,790 shares of Revolution Medicines worth $2.56B as of Q2 2026.
  • BlackRock bought 2,483,084 Revolution Medicines shares in Q2 2026, an estimated $363M.
  • Revolution Medicines made up 0.04% of BlackRock's portfolio in Q2 2026, its #375 holding.
  • BlackRock first reported a position in Revolution Medicines in Q1 2020 and has held it in 26 quarters since.
  • 690 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.